IP Library Granted Patent US 11,826,476
Granted Patent B2
US 11,826,476 · App. 16/676,395 · Granted Nov 28, 2023

Vaccine delivery systems using yeast cell wall particles

Inventors: Thomas E. Wagner (Greenville, SC); George E. Peoples, Jr. (Spring Branch, TX)
Assignee: ORBIS HEALTH SOLUTIONS, LLC
A61K9/5068A61K9/19A61K31/70A61K31/7088A61K39/0011A61K39/39C12N1/16A61K2039/5154A61K2039/55561A61K2039/55572A61K2039/55588A61K2039/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,826,476
App. No.
16/676,395
Granted
Nov 28, 2023
Kind
B2
Abstract

The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.

Claims (8)

1. A composition for delivering a vaccine, comprising (i) a yeast cell wall particle; (ii) a silicate; and (iii) an exogenous biological material loaded within the yeast cell wall particle, wherein the yeast cell wall particle is modified by coating with the silicate, wherein the biological material comprises a tumor lysate obtained from a tumor cell line.

2. The composition of claim 1 , wherein the silicate comprises an organic moiety attached to each of the four oxygen compounds of an orthosilicate.

3. The composition of claim 1 , wherein the silicate is selected from the group consisting of tetraethylorthosilicate, tetramethylorthosilicate, tetrapropylorthosilicate, and tetrabutylorthosilicate.

4. The composition of claim 1 , wherein the biological material loaded particle is further incubated with an isolated dendritic cell prior to administration.

5. The composition of claim 1 , further comprising one or more adjuvants, excipients, and preservatives.

6. The composition of claim 5 , wherein the adjuvant is monophosphoryl lipid A or a CpG oligonucleotide.

7. The composition of claim 1 , wherein the composition is freeze-dried.

8. The composition of claim 1 , wherein the tumor cell line is selected from breast cancer, small cell lung cancer, non-small cell lung cancer, glioma, medulloblastoma, neuroblastoma, Wilms tumors, rhabdomyosarcoma, osteosarcoma, liver cancer, pancreatic cancer, melanoma, prostate cancer, and ocular melanoma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2026
From: ORBIS HEALTH SOLUTIONS, LLC
To: ELIOS HOLDINGS, LLC
Reel/Frame 074417/0948 →
Continuity (5)
Continuation 15252999 · Aug 31, 2016
Continuation In Part PCTUS2015018728 · Mar 4, 2015
Provisional Application 62060124 · Oct 6, 2014
Provisional Application 61948503 · Mar 5, 2014
Related Publication 20200069596A1 · Mar 5, 2020